Skip to main content
JIN YANG PHARMACEUTICAL. CO., LTD logo

JIN YANG PHARMACEUTICAL. CO., LTD — Investor Relations & Filings

Ticker · 007370 ISIN · KR7007370000 KO Manufacturing
Open in API
Filings indexed 210 across all filing types
Latest filing 2024-12-20 Transaction in Own Shar…
Country KR South Korea
Listing KO 007370

About JIN YANG PHARMACEUTICAL. CO., LTD

https://www.jinyangpharm.com/

JIN YANG PHARMACEUTICAL. CO., LTD. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products, with a primary focus on prescription drugs. The company operates a fully automated, high-tech manufacturing facility. Its research and development efforts are dedicated to creating advanced preventive and therapeutic treatments for various diseases. Key areas of R&D include the development of anticancer drugs through molecular biology research, particularly for leukemia, and therapies for metabolic disorders such as diabetes and obesity. The company also develops antivirals and explores formulations based on herbal preparations.

Recent filings

Filing Released Lang Actions
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the extension of a trust contract for the acquisition of treasury shares (자기주식취득 신탁계약 연장결정). This type of filing specifically details the company's decision to buy back its own shares through a trust, which falls under the category of 'Transaction in Own Shares'.
2024-12-20 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Jinyang Pharmaceutical regarding the decision to pay a cash dividend. It specifies the dividend amount per share, the total dividend amount, the record date, and the approval process. This falls directly under the definition of a 'Notice of Dividend Amount'.
2024-12-16 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from Jinyang Pharmaceutical regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the upcoming 47th Annual General Meeting. It does not contain the full report or proxy materials themselves, but rather serves as a formal notice of a corporate action (setting a record date). Given the nature of the announcement and its brevity, it falls under the category of general regulatory filings.
2024-12-13 Korean
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory announcement from Jinyang Pharmaceutical regarding the setting of a record date for shareholder register closure for the purpose of dividend distribution. It explicitly states that this is a notice of the record date and that specific dividend details will be determined later. Since it announces the dividend record date rather than the final dividend amount or payment, it falls under general regulatory announcements.
2024-12-13 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the 'Acquisition of Convertible Bonds before Maturity' (전환사채 발행후 만기전 사채 취득). This filing details the specific financial transaction where the company repurchased its own convertible bonds due to a put option exercised by the bondholder. This falls under capital structure changes and financing updates, specifically related to debt management. Given the specific nature of the filing regarding bond acquisition/redemption, it fits best under the 'Capital/Financing Update' category.
2024-11-26 Korean
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the extension of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 연장결정). This involves the company's own share repurchase program. According to the provided definitions, reports regarding the company buying back or selling its own shares are classified as 'Transaction in Own Shares' (POS).
2024-11-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.